Rational adjustment of dose to reduce adverse reactions (RADAR) in patients with platinum-sensitive recurrent ovarian cancer: Results from the phase II NEWTON trial (ENGOT-ov49)

European Journal of Cancer 2026

View at publisher
Authors: NICOLETTA COLOMBO, Gabriella Parma, Giulia Tasca, Monica Palma, Germana Tognon, Andrea Alberto Lissoni, Roldano Fossati, Luciano Carlucci, Massimo Zucchetti, Cristina Matteo, Annamaria Ferrero, Alessandra Bologna
+16 more Mara Mantiero, Pauline Wimberger, Dionyssios Katsaros, Federica Tomao, Francesca Galli, Mariateresa Lapresa, Valentina Guarneri, Silvia Ficarelli, Stefania Canova, Silvia Derio, Fabio Girardi, Valentina Zizioli, Jalissa Katrini, Davide Massa, Eliana Rulli, Elena Cosenza Biagioli
DOI: 10.1016/j.ejca.2026.116685
Cited by: 1
References: 20

Fields of Study & Subjects

Ovarian cancer diagnosis and treatment PARP inhibition in cancer therapy Endometrial and Cervical Cancer Treatments

Publication details

Journal / source
European Journal of Cancer
Publisher
Elsevier BV
Volume
239
Pages
116685–116685
Publication date
28 March 2026
Language
EN